Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis ; volume:20 ; number:5 ; day:10 ; month:7 ; year:2023 ; pages:1284-1293 ; date:9.2023
Neurotherapeutics ; 20, Heft 5 (10.7.2023), 1284-1293, 9.2023
- Urheber
-
Lambru, Giorgio
Caponnetto, Valeria
Hill, Bethany
Ratti, Susanna
Sacco, Simona
Murphy, Madeleine
Briscoe, Jessica
Andreou, Anna P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13311-023-01394-0
- URN
-
urn:nbn:de:101:1-2023111511533193446457
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
10.01.20252025, 00:27 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lambru, Giorgio
- Caponnetto, Valeria
- Hill, Bethany
- Ratti, Susanna
- Sacco, Simona
- Murphy, Madeleine
- Briscoe, Jessica
- Andreou, Anna P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
CGRP and migraine: neurogenic inflammation revisited
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Anti-CGRP in cluster headache therapy: a response
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
CGRP-targeted medication in chronic migraine - systematic review
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
CGRP and migraine: neurogenic inflammation revisited
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Anti-CGRP in cluster headache therapy: a response
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
CGRP-targeted medication in chronic migraine - systematic review
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
CGRP and migraine: neurogenic inflammation revisited
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Anti-CGRP in cluster headache therapy: a response
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
CGRP-targeted medication in chronic migraine - systematic review
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?